NAV

Phorbol 12-myristate 13-acetate diester

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Phorbol 12-myristate 13-acetate diester
DrugBank Accession Number
DB17045
Background

Phorbol 12-myristate 13-acetate diester is an inducer of neutrophil extracellular traps (NETs).1

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 616.836
Monoisotopic: 616.397518763
Chemical Formula
C36H56O8
Synonyms
  • 12-o-tetradecanoylphorbol-13-acetate
  • 12-tetradecanoylphorbol 13-acetate
  • Phorbol 12-myristate 13-acetate
  • Phorbol myristate acetate
  • Pma (phorbol ester)
  • Tetradecanoylphorbol acetate
  • Tpa (phorbol ester)
External IDs
  • NSC-262244
  • PMA
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
NI40JAQ945
CAS number
16561-29-8
InChI Key
PHEDXBVPIONUQT-RGYGYFBISA-N
InChI
InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1
IUPAC Name
(1S,2S,6R,10S,11R,13S,14R,15R)-13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0^{2,6}.0^{11,13}]pentadeca-3,8-dien-14-yl tetradecanoate
SMILES
[H][C@]12[C@]3([H])C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@@]4([H])[C@@]3(O)[C@H](C)[C@@H](OC(=O)CCCCCCCCCCCCC)[C@@]1(OC(C)=O)C2(C)C

References

General References
  1. Masuda S, Kato K, Ishibashi M, Nishibata Y, Sugimoto A, Nakazawa D, Tanaka S, Tomaru U, Tsujino I, Ishizu A: Phorbol 12-myristate 13-acetate stimulation under hypoxia induces nuclear swelling with DNA outflow but not extracellular trap formation of neutrophils. Exp Mol Pathol. 2022 Apr;125:104754. doi: 10.1016/j.yexmp.2022.104754. Epub 2022 Mar 5. [Article]
KEGG Compound
C05151
ChemSpider
25977
ChEBI
37537
ChEMBL
CHEMBL279115
ZINC
ZINC000008214783

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentLeukemias1
1TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic and Myeloproliferative Disorders / Myelodysplastic Syndrome / Precancerous/Nonmalignant Condition1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000724 mg/mLALOGPS
logP5.53ALOGPS
logP5.69Chemaxon
logS-5.9ALOGPS
pKa (Strongest Acidic)12.57Chemaxon
pKa (Strongest Basic)-2.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area130.36 Å2Chemaxon
Rotatable Bond Count17Chemaxon
Refractivity169.32 m3·mol-1Chemaxon
Polarizability72.24 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at October 11, 2022 18:12 / Updated at December 01, 2022 11:34